3-hydroxyflavone has been researched along with Neoplasm Metastasis in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, HR; Chiou, HL; Hsieh, MH; Hsieh, YH; Lin, CL; Tsai, JP; Yang, SF | 1 |
| Chou, CH; Hsieh, YH; Lin, CW; Lu, KH; Yang, JS; Yang, SF | 1 |
| Grzanka, A; Grzanka, D; Hałas-Wiśniewska, M; Klimaszewska-Wiśniewska, A | 1 |
| Chang, CN; Chang, PC; Chen, JH; Lu, DY; Tsai, CF; Wang, SL; Yeh, WL | 1 |
| Chen, J; Li, R; Shao, S; Zhang, X; Zhao, Y | 1 |
| Chien, CS; Huang, JS; Ko, SC; Shen, KH; Shih, YW | 1 |
| Chao, CH; Chiang, TA; Lee, XY; Liao, YC; Shih, YW | 1 |
7 other study(ies) available for 3-hydroxyflavone and Neoplasm Metastasis
| Article | Year |
|---|---|
Fisetin Suppresses the Proliferation and Metastasis of Renal Cell Carcinoma through Upregulation of MEK/ERK-Targeting CTSS and ADAM9.
Topics: ADAM Proteins; Antineoplastic Agents; Carcinoma, Renal Cell; Cathepsins; Cell Movement; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Flavonoids; Flavonols; Humans; Kidney Neoplasms; MAP Kinase Signaling System; Membrane Proteins; Molecular Structure; Neoplasm Metastasis; Structure-Activity Relationship; Tumor Cells, Cultured | 2019 |
Dihydromyricetin suppresses cell metastasis in human osteosarcoma through SP-1- and NF-κB-modulated urokinase plasminogen activator inhibition.
Topics: Bone Neoplasms; Cell Line, Tumor; Cell Movement; Flavonols; Humans; Neoplasm Invasiveness; Neoplasm Metastasis; NF-kappa B; Osteosarcoma; Sp1 Transcription Factor; Urokinase-Type Plasminogen Activator | 2021 |
Evaluation of Anti-Metastatic Potential of the Combination of Fisetin with Paclitaxel on A549 Non-Small Cell Lung Cancer Cells.
Topics: A549 Cells; Actins; Antineoplastic Agents; Apoptosis; Biomarkers; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Flavonoids; Flavonols; Gene Expression Profiling; Humans; Lung Neoplasms; Neoplasm Metastasis; Paclitaxel; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; TOR Serine-Threonine Kinases; Vimentin | 2018 |
Fisetin inhibits cell migration via inducing HO-1 and reducing MMPs expression in breast cancer cell lines.
Topics: Cell Line, Tumor; Female; Flavonoids; Flavonols; Heme Oxygenase-1; Humans; Matrix Metalloproteinases; Neoplasm Metastasis; NF-E2-Related Factor 2; Triple Negative Breast Neoplasms | 2018 |
Fisetin inhibits migration, invasion and epithelial-mesenchymal transition of LMP1-positive nasopharyngeal carcinoma cells.
Topics: Carcinoma; Cell Line, Tumor; Cell Movement; Epithelial-Mesenchymal Transition; Flavonoids; Flavonols; Humans; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Invasiveness; Neoplasm Metastasis; Viral Matrix Proteins | 2014 |
Antimetastatic potential of fisetin involves inactivation of the PI3K/Akt and JNK signaling pathways with downregulation of MMP-2/9 expressions in prostate cancer PC-3 cells.
Topics: Cell Line, Tumor; Down-Regulation; Flavonoids; Flavonols; Humans; JNK Mitogen-Activated Protein Kinases; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Neoplasm Metastasis; Phosphatidylinositol 3-Kinases; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Signal Transduction | 2010 |
Involvement of the ERK signaling pathway in fisetin reduces invasion and migration in the human lung cancer cell line A549.
Topics: Anticarcinogenic Agents; Antineoplastic Agents; Cell Adhesion; Cell Line, Tumor; Cell Movement; Down-Regulation; Enzyme Inhibitors; Flavonoids; Flavonols; Humans; Lung Neoplasms; Matrix Metalloproteinase 2; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neoplasm Invasiveness; Neoplasm Metastasis; Phosphorylation; Signal Transduction; Urokinase-Type Plasminogen Activator | 2009 |